PL2948553T3 - Adenowirusowy system dostarczania i ekspresji terapii genowej zależny od pomocnika - Google Patents

Adenowirusowy system dostarczania i ekspresji terapii genowej zależny od pomocnika

Info

Publication number
PL2948553T3
PL2948553T3 PL14708933T PL14708933T PL2948553T3 PL 2948553 T3 PL2948553 T3 PL 2948553T3 PL 14708933 T PL14708933 T PL 14708933T PL 14708933 T PL14708933 T PL 14708933T PL 2948553 T3 PL2948553 T3 PL 2948553T3
Authority
PL
Poland
Prior art keywords
helper
gene therapy
expression system
therapy delivery
adenoviral gene
Prior art date
Application number
PL14708933T
Other languages
English (en)
Inventor
Zhechao Ruan
Kilian Guse
Brendan Lee
Original Assignee
Baylor College Of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Of Medicine filed Critical Baylor College Of Medicine
Publication of PL2948553T3 publication Critical patent/PL2948553T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10041Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/24Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
PL14708933T 2013-01-25 2014-01-27 Adenowirusowy system dostarczania i ekspresji terapii genowej zależny od pomocnika PL2948553T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361756516P 2013-01-25 2013-01-25
EP14708933.8A EP2948553B1 (en) 2013-01-25 2014-01-27 A helper-dependent adenoviral gene therapy delivery and expression system
PCT/IB2014/000071 WO2014115022A1 (en) 2013-01-25 2014-01-27 A helper-dependent adenoviral gene therapy delivery and expression system

Publications (1)

Publication Number Publication Date
PL2948553T3 true PL2948553T3 (pl) 2020-11-16

Family

ID=50239686

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14708933T PL2948553T3 (pl) 2013-01-25 2014-01-27 Adenowirusowy system dostarczania i ekspresji terapii genowej zależny od pomocnika

Country Status (6)

Country Link
US (4) US20150361452A1 (pl)
EP (1) EP2948553B1 (pl)
DK (1) DK2948553T3 (pl)
ES (1) ES2802878T3 (pl)
PL (1) PL2948553T3 (pl)
WO (1) WO2014115022A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2017129880A (ru) * 2015-01-26 2019-03-04 ЛУБРИС ЭлЭлСи Применение prg4 в качестве противовоспалительного средства
DK3402530T3 (da) 2016-01-13 2020-11-23 Genzyme Corp Rekombinante aav-vektorer, der udtrykker knoglebeskyttende gener, herunder has2 og lubricin, som er anvendelige til behandling af osteoarthritis og relaterede ledtilstande hos pattedyr
WO2018035441A1 (en) * 2016-08-19 2018-02-22 Colorado State University Research Foundation Methods and compositions for treating equine conditions using recombinant self-complementary adeno-associated virus
US11207382B2 (en) 2016-08-19 2021-12-28 University Of Florida Research Foundation, Incorporated Compositions for treating conditions using recombinant self-complementary adeno-associated virus
EP3500279A4 (en) * 2016-08-19 2020-04-22 Calimmune, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANINE CONDITIONS USING A RECOMBINANT SELF-COMPLEMENTARY ADENO-ASSOCIATED VIRUS.
KR20250121159A (ko) 2016-12-07 2025-08-11 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 인터류킨-1 수용체 길항제(IL-1RA) cDNA
JP7260173B2 (ja) 2017-04-21 2023-04-18 ベイラー カレッジ オブ メディスン 腫瘍溶解性ウイルス療法および免疫療法
US12624015B2 (en) 2019-06-24 2026-05-12 University Of Iowa Research Foundation JNK inhibitors as anticancer agents
BR112022004906A2 (pt) * 2019-09-18 2022-06-28 Pacira Therapeutics Inc Dosagens eficazes de um sistema de liberação e expressão biológica à base de adenovírus para o uso no tratamento de osteoartrite em humanos, e composições compreendendo as mesmas
WO2021086973A2 (en) * 2019-10-28 2021-05-06 University Of Iowa Research Foundation Formulation for delivery of lubricin gene
AU2024228620A1 (en) 2023-03-02 2025-08-28 Pacira Germany Gmbh Compositions and methods for improved adenoviral- based gene therapy utilizing corticosteroid treatment

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747072A (en) * 1993-07-30 1998-05-05 University Of Michigan Adenoviral-mediated gene transfer to synovial cells in vivo
US6960562B2 (en) * 1999-04-23 2005-11-01 Rhode Island Hospital, A Lifespan Partner Tribonectin polypeptides and uses thereof
US6743774B1 (en) * 1999-04-23 2004-06-01 Rhode Island Hospital Tribonectins
AU2002311777A1 (en) * 2001-04-17 2002-10-28 Genetix Pharmaceuticals, Inc. Method of treating arthritis using lentiviral vectors in gene therapy
CA2451955C (en) 2001-06-26 2015-09-29 Abgenix, Inc. Antibodies to opgl
UA91818C2 (ru) * 2003-08-14 2010-09-10 Уайт Рекомбинантные молекулы лубрицина и их использование
EP2034025A1 (en) * 2007-09-04 2009-03-11 Freie Universität Berlin Inflammation-induced anti-inflammatory gene expression
US20090104148A1 (en) * 2007-09-18 2009-04-23 Jay Gregory D Treatment and prevention of joint disease
EP2217258B1 (en) * 2007-11-14 2014-03-26 General Regeneratives Limited Use of interleukin-1 receptor antagonist as a myeloprotective agent
US8877445B2 (en) * 2008-11-14 2014-11-04 Intelligent Oncotherapeutics, Inc. Methods for identification of tumor phenotype and treatment
US20100215731A1 (en) * 2009-02-20 2010-08-26 Maastricht University Method for improving cartilage repair and/or preventing cartilage degeneration in a joint
PL2623604T3 (pl) * 2012-02-02 2015-07-31 Baylor College Medicine Biologiczny system dostarczania i ekspresji oparty na adenowirusie do zastosowania w leczeniu choroby zwyrodnieniowej stawów
WO2015060935A1 (en) * 2013-10-22 2015-04-30 Lubris, Llc Control of rheological properties of mixed hyaluronate/lubricin solutions

Also Published As

Publication number Publication date
US11746359B2 (en) 2023-09-05
US20220282280A1 (en) 2022-09-08
US20240102049A1 (en) 2024-03-28
EP2948553A1 (en) 2015-12-02
US20220017923A1 (en) 2022-01-20
EP2948553B1 (en) 2020-04-01
WO2014115022A1 (en) 2014-07-31
DK2948553T3 (da) 2020-06-29
US20150361452A1 (en) 2015-12-17
ES2802878T3 (es) 2021-01-21

Similar Documents

Publication Publication Date Title
ZA201507315B (en) Selective gene therapy expression system
GB2508608B (en) Data delivery
GB201215193D0 (en) Order delivery system
GB2531176B (en) Fluid delivery system
ZA201509309B (en) Transdermal delivery system
ZA201406597B (en) Nasal delivery devices
ZA201406596B (en) Nasal delivery devices
ZA201502351B (en) Flexible anchor delivery system
IL245544A0 (en) drug delivery system
ZA201503613B (en) Recombinant adenoviruses and use thereof
PL2817053T3 (pl) Urządzenia do podawania donosowego
AU350056S (en) Drug delivery assembly control unit
HUE053136T2 (hu) Optimizált VIII. faktor gén
SG10201704720RA (en) Interface and fluid-transfer system
DK2948553T3 (da) Hjælper-afhængigt afgivelses- og ekspressionssystem til adenoviral genterapi
PL3011037T3 (pl) Gen oporności na rizomanię
EP2830693A4 (en) NARCOSEGAS DELIVERY SYSTEM
LT2908873T (lt) Transderminio įvedimo sistema
GB201213491D0 (en) Content delivery system
SG10201609440WA (en) Multi-additive delivery system
EP3042715A4 (en) LIQUID DELIVERY SYSTEM
EP2925650A4 (en) BULLETIN SYSTEM AND USE
GB201214708D0 (en) Secure delivery system
GB201206046D0 (en) Nasal delivery devices
GB201206052D0 (en) Nasal delivery devices